Bris­tol-My­ers part­ner In­nate con­cedes a PhII flop for I/O drug lir­ilum­ab in fight­ing AML

More than five years ago Bris­tol-My­ers Squibb her­ald­ed a $465 mil­lion deal to part­ner with In­nate Phar­ma on its nat­ur­al killer cell can­cer drug lir­ilum­ab. But to­day the French biotech was forced to con­cede that its lead drug was no bet­ter than a place­bo in fight­ing acute myeloid leukemia as a monother­a­py.

Car­ry­ing out plans to han­dle de­vel­op­ment through Phase II, Mar­seilles-based In­nate ex­ecs said that lir­ilum­ab flunked a Phase II tri­al test­ing the drug as a sin­gle agent. There was no ev­i­dence that the drug was any bet­ter than place­bo in spurring a leukemia-free out­come for pa­tients in a main­te­nance set­ting.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER